<DOC>
	<DOC>NCT00351585</DOC>
	<brief_summary>Type 2 diabetes results when the body does not produce enough insulin to regulate blood sugar. This study is designed to measure the effect of vildagliptin on the maximum insulin secretion by the pancreas.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diagnosed with type 2 diabetes for at least 6 months Patients whose diabetes is controlled by diet and exercise only or patients taking metformin BMI in the range 2245 Blood glucose criteria must be met Pregnancy or lactation Type 1 diabetes or diabetes resulting from pancreatic injury Cardiovascular complications as defined by the protocol Significant diabetic complications as defined by the protocol Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vildagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Insulin secretion</keyword>
	<keyword>Beta cell</keyword>
</DOC>